Overview
The objective of this randomized study is to compare the safety and efficacy of the ultra-low strut thickness everolimus-eluting biodegradable polymer Evermine50 stent to the everolimus-eluting family stents (durable polymer everolimus-eluting Xience or Promus stents) in a population-based setting with coronary artery stenosis treated with percutaneous coronary intervention
Eligibility
Inclusion Criteria:
- All patients aged ≥18 years who are eligible for treatment with one or several drug-eluting coronary stents
Exclusion Criteria:
- Age < 18 years
- Not able to consent to study participating (eg. intubated patients)
- Unstable circuit or in cardiogenic shock and therefore not able to understand the information and purpose of the study
- Do not speak Danish
- Already included in the SORT OUT XII study
- Life expectancy <1 year
- Allergic to study related treatment